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Abstract
We have developed a self-assembled nanoparticle (NP) that efficiently delivers small interfering
RNA (siRNA) to the tumor by intravenous (IV) administration. The NP was obtained by mixing
carrier DNA, siRNA, protamine, and lipids, followed by post-modification with polyethylene glycol
and a ligand, anisamide. Four hours after IV injection of the formulation into a xenograft model, 70–
80% of injected siRNA/g accumulated in the tumor, ~10% was detected in the liver and ~20%
recovered in the lung. Confocal microscopy showed that fluorescent-labeled siRNA was efficiently
delivered into the cytoplasm of the sigma receptor expressing NCI-H460 xenograft tumor by the
targeted NPs, whereas free siRNA and non-targeted NPs showed little uptake. Three daily injections
(1.2 mg/kg) of siRNA formulated in the targeted NPs silenced the epidermal growth factor receptor
(EGFR) in the tumor and induced ~15% tumor cell apoptosis. Forty percent tumor growth inhibition
was achieved by treatment with targeted NPs, while complete inhibition lasted for 1 week when
combined with cisplatin. The serum level of liver enzymes and body weight monitoring during the
treatment indicated a low level of toxicity of the formulation. The carrier itself also showed little
immunotoxicity (IMT).
INTRODUCTION
Selective oncogene silencing, mediated by small interfering RNA (siRNA), shows promise for
cancer treatment. However, the obstacles in successfully delivering siRNA hinder the
therapeutic viability of this treatment.1–3 siRNA are susceptible to nuclease destruction and
cannot penetrate the cell membrane when used in vivo due to the highly charged nucleic acid
backbone. Although a variety of delivery systems have been developed for siRNA,2,4–16 the
majority of the injected dose (ID) was taken up by the reticular endothelial system in the liver
and spleen.17 This typically left only 2–5% of the ID/g tissue for the tumor;14,17 therefore, a
more efficient delivery system still needs to be found.
Previously, we have shown that our nanoparticles (NPs) could efficiently deliver siRNA to the
sigma receptor–expressing lung tumor cells (NCI-H1299), stimulate strong RNA interference
effects and induce >80% apoptosis in vitro.18 The targeting ligand, anisamide, used in the
formulation had a moderate affinity (estimated at Kd ~30 nmol/l) for sigma receptors and was
shown to increase the intracellular delivery into prostate and lung cancer cells.18–20 In this
study, we used a more aggressive lung cancer cell line, NCI-H460, to grow highly vasculatured
tumors in vivo. This is a pre-requisite for the enhanced permeability and retention effect of any
NP-based delivery systems.21 We hypothesized that the encapsulated siRNA is protected by
the NPs and thus would accumulate in the tumor with an improved efficiency. The addition of
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anisamide ligand might also further increase the cellular uptake and enhance the RNA
interference effect.
The therapeutic target in this study was the epidermal growth factor receptor (EGFR). EGFR
is over-expressed in a variety of tumors and has been shown to be associated with many adverse
features of tumor, including increased proliferation, decreased apoptosis, enhanced metastasis,
and resistance to chemo- and radiation therapy.22,23 AntiEGFR therapy via tyrosine kinase
inhibitors and monoclonal antibody has demonstrated great benefit for cancer patients.24–27
Silencing EGFR by RNA interference is an alternative to antiEGFR therapy and has already
shown some promising results.28–35 EGFR silencing induces cell cycle arrest, apoptosis, tumor
cell growth inhibition, and chemosensitization in vitro and in vivo.28–35 In the in vitro
preliminary studies (methods described in Supplementary Materials and Methods), we showed
that the targeted NP delivered a significantly higher amount of siRNA into NCI-H460 cells
and showed a stronger gene silencing effect compared to non-targeted NP (Supplementary
Figure S1). Targeted NP silenced the EGFR at the concentration of 120 nmol/l (Supplementary
Figure S1b). The cytotoxicity of the NP was siRNA sequence and formulation dependent
(Supplementary Figure S2). The cell death mechanism was confirmed to be apoptosis by means
of immunostaining of the apoptosis inducing factor (AIF) (Supplementary Figure S2b).
RESULTS
Pharmacokinetic studies, tissue distribution, and intracellular uptake of siRNA
Free FAM-siRNA (fluorescein-labeled siRNA) was eliminated rapidly from the blood and the
concentration was under the detection limit after a 40-minute time point (Figure 1). In 40
minutes, only 1% ID of free siRNA was detected in the blood. No significant difference in the
pharmacokinetic (PK) profiles was observed between the tumor free and the tumor-bearing
mice treated with free siRNA. NP significantly prolonged the circulation of siRNA and there
was no difference in PK between the targeted and non-targeted NPs. NPs showed a rapid
distribution phase, in which serum concentrations dropped to 1/10 within 40 minutes. After
that, concentrations remained steady for at least 24 hours. Tumor-bearing mice cleared the NPs
from the blood significantly quicker than the tumor free mice. In 2 minutes, almost a 100% ID
of the NPs remained in the blood of the tumor free mice, while only a 25% ID remained in that
of the tumor-bearing mice. At the terminal phase (80 minutes–24 hours), a 5–10% ID was
detected in the blood of the tumor free mice, while only 1–2% ID was recovered in that of the
tumor-bearing mice. The dose recoveries in the major organs of mice treated with free siRNA
and siRNA in NP were ~30 and 60%, respectively.
The PK profiles were fitted with a non-compartment model using the WinNonlin program and
the key PK parameters were obtained (Table 1). For free siRNA, the parameters obtained from
the tumor free and the tumor-bearing mice were similar to each other. NPs significantly
increased the terminal phase half-life (t1/2) 80-fold to 100-fold, and increased the area under
the curve 15-fold to 100-fold and decreased the clearance 15-fold to 100-fold for siRNA. Again,
there was no difference between the parameters of targeted and non-targeted NPs. However,
the presence of tumor significantly changed some of the parameters of the NP. The area under
the curve was reduced fourfold to sixfold, the clearance was increased fourfold to sixfold, and
the steady state volume of distribution (Vss) was increased fivefold to sixfold in the tumor-
bearing mice compared to the tumor free mice. The t1/2 and mean residence time remained
unchanged in the presence of tumor.
We employed Xenogen IVIS imaging system to visualize the FAM-siRNA distribution in
major tissues in the mice 4 hours after intravenous (IV) injections. As shown in Figure 2a,
fluorescence signals were hardly detected in the tissues collected from the mice treated with
free siRNA. While the liver showed the strongest signal, it was still minimal. Among the tissues
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excised from the mice treated with NP, the NCI-H460 xenograft tumors showed the strongest
signal and all other tissues showed only background to moderate signals. In the quantitative
results (Figure 2b), the liver, lung, and tumor showed comparable uptake of free siRNA ranging
from 10 to 20% ID/g. Other tissues showed minimal uptake of free siRNA (<5% ID/g). Non-
targeted and targeted NP had similar tissue distribution patterns, in which 70–80% ID/g
accumulated in the tumor, whereas both the lung and liver took up <20% ID/g. The uptake of
siRNA formulated in NP was under the detection limit in the heart, spleen, and kidney. The
bioavailability of siRNA in the tumor tissues was examined by confocal microscopy. As shown
in Figure 3 (xyz images) and Supplementary Figure S3, the targeted NP showed strong
cytosolic delivery of FAM-siRNA, while the non-targeted NP was less efficient in intracellular
delivery and free siRNA showed no delivery. The percentages of fluorescence positive cells
for free siRNA, non-targeted NP, and targeted NP were <1%, 5%, and 30%, respectively. The
distribution of fluorescence in the tumor was heterogeneous. We used z-axis imaging to further
address the intracellular delivery efficiency. Blue arrows indicate the extracellular space and
pink arrows show the intracellular uptake of FAM-siRNA (Figure 3 xzy images and
Supplementary Figure S4). A majority of the siRNA formulated in non-targeted NPs remained
in extracellular space while the siRNA in targeted NPs was mostly internalized into the cells.
EGFR gene silencing, apoptosis induction, and tumor growth inhibition
To examine the biological activities of siRNA, EGFR levels in the tumor were detected by
immunohistochemistry (Figure 4a upper and Supplementary Figure S5) and Western blot
analysis (Figure 5). The EGFR in NCI-H460 tumor was silenced by siRNA in targeted NPs.
The non-targeted NPs showed only a partial effect, whereas free siRNA and the control siRNA
in targeted NPs showed no effect. We also examined the apoptotic markers in the tumor (Figure
4a middle and bottom and Supplementary Figures S6 and S7). Prostate apoptotic response 4
levels were elevated after the treatment of siRNA in targeted NPs, while siRNA in non-targeted
NPs showed only a moderate effect. Other control treatments had little effect. Immunostaining
of the AIF showed similar results, in which siRNA in targeted NPs induced significant nuclear
translocation of AIF (Figure 4a bottom and Supplementary Figure S7, P < 0.01). We calculated
the percentage of AIF nuclear translocation to quantify the percentage of apoptosis. Tumor
apoptosis in mice treated with phosphate- buffered saline, free siRNA, siRNA in non-targeted
NPs, siRNA in targeted NPs, and control siRNA in targeted NPs were 2, 3, 7, 15, and 3%,
respectively (Figure 4b). Three injections of siRNA in targeted NPs showed a partial inhibition
of tumor growth (P < 0.01 at day 10) similar to that of intraperitoneal cisplatin (P < 0.05 at
day 7) (Figure 6). However, 2 weeks later, the tumor growth rate became comparable to the
untreated control. Other control treatments had no effects. Combination of siRNA (formulated
in targeted NP) and cisplatin completely inhibited tumor growth for an entire week (P < 0.001
at day 7). Tumor growth, however, resumed after 1 week.
Toxicity and immune response studies in normal mice
As shown in Figure 7a, siRNA alone (group B) or when formulated with calf thymus DNA
into NPs induced a very mild production of inflammatory cytokines in the athymic nude mice
(groups C–E). However, when plasmid DNA was co-formulated with siRNA (group G), the
formulation became very immunogenic. In the C57BL/6 mice model (Figure 7b), free siRNA
(group B) did not induce cytokine production, while siRNA formulated in NPs (groups C and
D) induced a significant production of all analyzed cytokines, except for the tumor necrosis
factor. Targeted NPs (group D) induced higher levels of cytokines compared to the non-targeted
formulation (group C). Unexpectedly, targeted NPs containing murine double minute 2
(MDM2) siRNA (with no identifiable immunostimulatory motifs, group E) induced
significantly higher levels of cytokines than the one containing EGFR siRNA (group D). Empty
NP (group F) showed very mild (IMT) immunotoxicity. When using plasmid as the carrier
DNA in the targeted NP formulation (group G), all inflammatory cytokines were induced to
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high levels. Additionally, serum levels of aspartate aminotransferase and alanine
aminotransferase in mice treated with siRNA in different formulations were all in the normal
range (Supplementary Figure S8) the method is described in the Supplementary Materials and
Methods. Mouse body weight did not change significantly during the siRNA treatment
(Supplementary Figure S9).
DISCUSSION
The self-assembled NP without surface modification was developed earlier in our lab for
plasmid DNA delivery.36 In this study, we reformulated the NP by replacing the plasmid DNA
with a mixture of siRNA and calf thymus DNA. The resulting complex was further coated with
polyethylene glycol-lipids for improved stability. The calf thymus DNA served as a carrier in
the formulation, which reduced the particle size by 10–30% and increased delivery efficiency
by 20–80% (data not shown). This may be due to improved core compaction provided by high
molecular weight DNA. The calf thymus DNA also contains limited amounts of
immunostimulating CpG motifs37 and thus provides a lower potential for IMT than plasmid,
which was supported by Figure 7.
The PK results suggest that the majority of the free siRNA was eliminated from the blood
before it accumulated in the tissues. On the other hand, the tumor appeared to be the major
uptake tissue for NPs and contributed a high uptake (70–80% ID/g) (Figure 2b). Additionally,
the liver and lung only took up 10–20% ID/g, which shows the high tumor selectivity of the
NPs. The slightly positive charge of the NP (zeta potential 15–20 mV) may contribute to the
relatively higher uptake in the lung, the first pass organ. The reason the NP delivered a majority
of the dose to the tumor, instead of the liver, remains unknown at the present time. We
hypothesize that the particle size of the NP (120–150 nm) is too big to penetrate the liver
fenestrae (pore size ~100 nm)38 but still small enough to extravasate through the leaky
capillaries in the tumor tissue (pore size ~400 nm).39 Similar results were reported by Pirollo
et al.10,40 With a size of ~200 nm, their nanoimmunoliposome complex delivered siRNA
specifically to primary and meta-static tumors with minimal liver uptake. The increase of Vss
for NPs in the tumor-bearing mice as compared to that of the tumor free mice suggests that the
tumor served as a distribution sink for NPs. The decrease in the area under the curve and
increase in clearance are also consistent with this observation. The presence of the targeting
ligand facilitated the internalization of siRNA by the tumor cells (Figure 2 and Supplementary
Figures S3 and S4) but did not alter the PK (Figures 1 and 2). The results indicate that
extravasation of the vector, which was mainly dependent on the enhanced permeability and
retention effect, was the rate limiting factor. Enhanced intracellular uptake of the vector did
not cause further clearance. The internalization of siRNA formulation in the tumor was uneven
(Figure 2 and Supplementary Figure S3), suggesting that cells closer to the angiogenic
capillaries are likely to take up more siRNA. However, the EGFR silencing in the entire tumor
was nearly complete (Figures 4a upper and 5, and Supplementary Figure S5). This suggests
only small amounts of siRNA, as long as properly delivered, are necessary for effective gene
silencing. The in vivo RNA interference effect was highly dependent on the formulation and
siRNA sequence. Only siRNA formulated in targeted NPs showed significant gene silencing
activity (Figures 4a upper and 5, and Supplementary Figure S5). This targeted formulation also
showed good efficiency in inducing apoptosis in the tumor (15%, P < 0.05) (Figure 4b),
inhibiting tumor growth (~40%, P < 0.01 on day 10) and sensitizing the tumor to chemotherapy
(Figure 6).
The cytokine induction effect was dependent on the model, formulation, and siRNA sequence.
The results in Figure 7a showed that the immune response of the nude mice were not sensitive
to siRNA but to CpG motifs. siRNA-mediated immune response is via toll-like receptor 7/8
(TLR7/8),41,42 suggesting that the toll-like receptor 7/8 may be not be expressed or only at a
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low level in the nude mice. On the other hand, the toll-like receptor 9 was shown to be a good
immunostimulatory target by CpG oligonucleotides in nude mice,43 and, therefore, a
formulation containing plasmid showed strong IMT (Figure 7a). In the C57BL/6 model, when
siRNA was formulated into the NP, the immunostimulatory effect was strengthened (Figure
7b). Additionally, the presence of the targeting ligand in the formulation increased the IMT of
siRNA. This is probably due to the increased cellular uptake through endosomal pathway.
Surprisingly, MDM2 siRNA containing no identifiable inflammatory sequences induced
higher levels of cytokines than EGFR siRNA containing the immunostimulatory sequence (5′-
UGUGU-3′) (Figure 7b). MDM2 siRNA may contain some unknown, yet potent, sequences
that induced the production of cytokines. Another possibility is that different toll-like receptor
isoforms might be involved in the immunostimulatory effect of MDM2 siRNA, which is
suggested by Wang and colleagues.44 More importantly, empty NP (group F) showed very
mild IMT (Figure 7a and b), suggesting the carrier itself was safe.
Although several siRNA delivery systems have exhibited high activity against tumors in
vivo,2,4–16 our NP formulation provides the advantages of an almost complete encapsulation
efficiency (>95%), the highest tumor delivery efficiency so far reported (70–80% ID/g at 4
hours) (Figure 2b) and relatively easy preparation. Our carrier also showed low toxicity (Figure
7 and Supplementary Figures S8 and S9).
MATERIALS AND METHODS
Materials
NCI-H460 (human lung cancer cells) were obtained from American Type Culture Collection.
Cells were maintained in Roswell Park Memorial Institute medium 1640 supplemented with
10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml penicillin, and 100 μg/ml
streptomycin (Invitrogen, Carlsbad, CA). NCI-H460 cells were shown to be sigma receptor
positive by immunostaining and Western blot (data not shown). Primary antibodies against
EGFR (rabbit polyclonal), prostate apoptotic response 4 (mouse monoclonal), AIF (rabbit
polyclonal) and actin/β-actin (mouse monoclonal) were purchased from Santa Cruz
Biotechnologies (Santa Cruz, CA).
Experimental animals
Female athymic nude mice of age 6–8 weeks and female C57BL/6 mice of age 6–7 weeks (16–
18 g) were purchased from Charles River Laboratories (Wilmington, MA). All work performed
on animals was in accordance with and permitted by the University of North Carolina
Institutional Animal Care and Use committee.
NP preparations
NPs were prepared by the method described previously,18,20 except that the DSPE-PEG
amount was reduced to half. DSPE-PEG-anisamide for the modification of the NPs was
synthesized according to the published method.19 Control siRNA that targets the sequence 5′-
AATTCTCCGAACGTGTCACGT-3′ and EGFR siRNA that targets the sequence 5′-
AACACAGTGGAGCGAATTCCT-3′ as described previously35 were synthesized in
Dharmacon (Lafayette, CO). The control sequence does not match any human genome
sequence. FAM-siRNA was also obtained from Dharmacon (Lafayette, CO).
PK study
NCI-H460 cells (5 × 106) were subcutaneously injected into the right flank of nude mice. When
tumors reached the size of ~1 cm2, mice were IV injected with FAM-siRNA in different
formulations at the dose of 1.2 mg/kg. At different time points, 50–100 μl of blood was collected
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from the tail artery and serum was isolated. Ten microliters of serum was mixed with 90 μl of
lysis buffer (0.1% sodium dodecyl sulfate in phosphate- buffered saline) and incubated at 65
°C for 10 minutes, followed by the addition of 200 μl methanol and incubation at 65 °C for 10
minutes. The sample was centrifuged at 14,000 rpm for 5 minutes and 200 μl supernatant was
transferred to a black 96-well plate (Corning, Corning, NY). The fluorescence intensity of the
sample was measured by a plate reader (Bioscan, Washington, DC) at λex: 485 nm and λem:
535 nm. FAM-siRNA concentration in each sample was calculated from a standard curve. This
extraction method provided 98% recovery of free FAM-siRNA and 48% recovery for FAM-
siRNA containing NP. The FAM-siRNA concentration was corrected for the degree of sample
recovery.
Tissue distribution and tumor uptake study
Mice with tumor size of ~1 cm2 were IV injected with FAM-siRNA in different formulations
(1.2 mg/kg). Four hours later, mice were killed and tissues were collected and imaged by the
IVIS Imaging System (Xenogen Imaging Technologies, Alameda, CA). To quantify the
accumulated doses, the excised tissues were homogenized in 300 or 1,000 μl lysis buffer (1,000
μl for livers and 300 μl for others) and incubated at 65 °C for 10 minutes. One hundred micro-
liter of supernatant was collected after centrifugation at 14,000 rpm for 10 minutes. FAM-
siRNA in the supernatant was extracted and quantified by the method described in the PK
study. The accumulated dose in each tissue was calculated from a standard curve obtained by
spiking known amounts of FAM-siRNA or FAM-siRNA containing NP in tissues obtained
from uninjected animals. Alternatively, tumors were sectioned (7 μm thick) by a cryostat (H/
I Hacker Instruments & Industries, Winnsboro, SC). Sections were counterstained with 4′,6-
diamidino-2-phenylindole and imaged using a Leica SP2 confocal microscope.
Immunohistochemistry and Western blot
NCI-H460 xenograft tumor-bearing mice (tumor size ~1 cm2) were IV injected with siRNA
in different formulations (1.2 mg siRNA/kg, one injection per day for 3 days). One day after
the third injection, mice were killed and tumor samples were collected. Tumors were frozen-
sectioned and 7 μm thick section samples were immunostained with primary antibodies and
visualized with kits from Dakocytomation [DakoCytomation Envision + Dual Link System-
HRP (DAB+), DakoCytomation, Carpinteria, CA]. Samples were imaged by using a Nikon
Microphot SA microscope. The percentage of AIF nuclear localization was calculated based
on 30 random images obtained from three individual tumors. Total protein (40 μg) isolated
from the tumors was loaded on a polyacrylamide gel and electrophoresed. Protein bands in the
gel were then transferred to a polyvinylidene difluoride and the EGFR was probed by
antibodies. The level of the target proteins in each lysate was detected by enhanced
chemiluminescence using ChemiGlow (Alpha Innotech, San Leandro, CA) followed by
detection by the AlphaImager (Alpha Innotech, San Leandro, CA).
Tumor growth inhibition study
NCI-H460 xenograft tumor-bearing mice (size 25–40 mm2) were IV injected with siRNA
containing formulations at the dose of 1.2 mg/kg (one injection per day for 3 days). For the
chemo-combination treatment, cisplatin (3 mg/kg) were intraperitoneally administered from
the 3rd to 5th day after the first siRNA injection. Tumor growth in the treated mice was
monitored thereafter. Mouse body weight was also monitored.
Cytokine induction studies
Female athymic nude mice or C57BL/6 mice were injected with siRNA in different
formulations at the dose of 1.2 mg siRNA/kg. Two hours after the injection, blood samples
were collected and serum was isolated. Tumor necrosis factor, interleukin-6, interleukin-12
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(BD Biosciences, San Diego, CA) and interferon-α levels (PBL Biomedical Laboratories,
Piscataway, NJ) were measured by enzyme-linked immunosorbent assay according to the
manufacturer’s protocol. MDM2 siRNA (target sequence: 5′-
GCUUCGGAACAAGAGACUC-3′) without any known immunostimulatory sequences (5′-
GUCCUUCAA-3′ and 5′-UGUGU-3′)45,46 was used as a negative control. Calf thymus DNA
alone was formulated into targeted NPs and injected into the mice at the dose of 2.4 mg DNA/
kg. This formulation is also regarded as the empty NP (without siRNA). Targeted NPs
containing EGFR siRNA and luciferase plasmid DNA were also prepared and injected.
Statistical analysis
All statistical analyses were performed by a two- tailed student t-test. Data were considered
statistically significant when P value was less than 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Serum concentration profiles of FAM-siRNA in different formulations
Data = mean ± SD, n = 4–8. NP, nanoparticle; siRNA, small interfering RNA.
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Figure 2. Tissue distribution study
(a) Fluorescence signal of FAM-siRNA in different tissues detected by the Xenogen IVIS
imaging system. (b) Tissue distribution of FAM-siRNA in different formulations. Data = mean
± SD, n = 3–4. NP, nanoparticle; siRNA, small interfering RNA.
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Figure 3. Tumoral uptake of FAM-siRNA in different formulations
Blue arrows indicate the extracellular space and pink arrows indicate the intracellular uptake
of FAM-siRNA. Magnification = ×400 (xyz images), ×630 (xzy images). NP, nanoparticle;
siRNA, small interfering RNA.
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Figure 4. Immunohistochemical analysis of the tumor samples
(a) Immunohistochemical staining on tumor sections: epidermal growth factor receptor
(upper), prostate apoptotic response 4 (middle), and apoptosis inducing factor (AIF) (bottom).
Magnification = ×200. (b) Quantitative analysis of nuclear translocation of AIF in the tumors
treated with different formulations. **indicates P < 0.01, *indicates P < 0.05. NP, nanoparticle;
PBS, phosphate-buffered saline; siRNA, small interfering RNA.
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Figure 5. Western blot analysis of epidermal growth factor receptor (EGFR) in the NCI-H460
xenograft tumor after treatment with different formulations
NP, nanoparticle; PBS, phosphate-buffered saline; siRNA, small interfering RNA.
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Figure 6. NCI-H460 xenograft tumor growth inhibition by small interfering RNA (siRNA) in
different formulations with or without the combination of cisplatin
Solid arrows indicate the intravenous administrations of siRNA (1.2 mg/kg) and dash-line
arrows indicate the intra-peritoneal injections of cisplatin (3 mg/kg). Data = mean, n = 6–9.
SD of the data points is not shown for clarity.
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Figure 7. Serum cytokine analysis
Serum cytokine levels in the (a) athymic nude mice and (b) C57BL/6 mice 2 hours after the
injection of different formulations at the dose of 1.2 mg siRNA/kg (2.4 mg DNA/kg for group
F). A, phosphate-buffered saline (PBS); B, epidermal growth factor receptor (EGFR) small
interfering RNA (siRNA) in PBS; C, EGFR siRNA and calf thymus DNA in non-targeted
nanoparticle (NP); D, EGFR siRNA and calf thymus DNA in targeted NP; E, MDM2 siRNA
and calf thymus DNA in targeted NP; F, calf thymus DNA in targeted NP (empty NP); G,
EGFR siRNA and plasmid DNA in targeted NP. Data = mean ± SD, n = 3–8.
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